Skip to main content.

Shane Stecklein, M.D., Ph.D.

Shane Stecklein portrait
Assistant Professor, Radiation Oncology

Assistant Professor, Pathology and Laboratory Medicine

Assistant Professor, Cancer Biology

sstecklein@kumc.edu

Professional Background

Dr. Shane Stecklein is an Assistant Professor of Radiation Oncology at The University of Kansas School of Medicine and The University of Kansas Cancer Center, and he serves as the Director of Translational Research for Radiation Oncology. He specializes in the treatment of breast cancer and lymphoma/myeloma.

Dr. Stecklein received his B.S. in Cell Biology from The University of Kansas, and then received his M.D. and Ph.D. (Molecular and Experimental Pathology) in the Medical Scientist Training Program at The University of Kansas School of Medicine. He then completed an internship in Internal Medicine at The University of Texas Health Science Center at Houston and a residency in Radiation Oncology at The University of Texas MD Anderson Cancer Center. He also completed a research fellowship in Experimental Radiation Oncology during residency.

Dr. Stecklein is Co-Chair of the Breast Disease Working Group at The University of Kansas Health System, and he serves as the PI or institutional PI for several investigator-initiated and national cooperative trials in breast cancer radiotherapy. Nationally, he is a member of the Breast Committee and the Breast Translational Medicine Working Group for the Southwest Oncology Group (SWOG) cooperative clinical trials network, and he serves on the Breast Oncology Local Disease (BOLD) Task Force for the National Cancer Institute's Breast Cancer Steering Committee. He is also a member of numerous professional organizations, including the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), and the American Association for Cancer Research (AACR).

Education and Training
  • PhD, Molecular and Experimental Pathology, The University of Kansas School of Medicine, Kansas City, KS
  • MD, Medicine, The University of Kansas School of Medicine, Kansas City, KS
  • BS, Cell Biology, The University of Kansas, Lawrence, KS
  • Residency, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Post Doctoral Fellowship, Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center
  • Internship, Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX
Licensure, Accreditations & Certifications
  • Board Certified (Radiation Oncology), American Board of Radiology
  • Medical Physician & Surgeon - Kansas License, Kansas Board of healing Arts
  • Medical Physician & Surgeon - Missouri License, Missouri Board of Registration for the Healing Arts

Research

Overview

In addition to his primary appointment in Radiation Oncology, Dr. Stecklein holds joint appointments as Assistant Professor in the Department of Pathology andamp; Laboratory Medicine and the Department of Cancer Biology. He leads a basic-translational research laboratory that aims to understand the molecular pathogenesis of triple-negative breast cancer (TNBC) and the interplay between genomic instability, the tumor microenvironment, and response to therapy in TNBC. Dr. Stecklein uses a combination of in vitro and in vivo molecular, genetic, and computational approaches to work towards his long-term goals of defining and optimizing personalized treatment strategies for TNBC and translating promising pre-clinical findings into early-stage therapeutic trials.

Dr. Stecklein is also passionate about cancer education and global oncology. He teaches radiation and cancer biology to trainees at The University of Kansas, The University of Texas MD Anderson Cancer Center, and internationally to African clinical oncology residents through a partnership with Cancer Diseases Hospital in Lusaka, Zambia. He is also the Radiation and Cancer Biology Editor for RadOncQuestions.com, a widely used educational resource for radiation oncology trainees preparing to take their board certification examinations.

Current Research and Grants
  • ctDNA and exoRNA Predict TNBC Recurrence After Chemotherapy or Chemoimmunotherapy, Kansas Institute for Precision Medicine COBRE, PI
Publications
  • Villodre, E., S, Hu, X, Larson, R, Finetti, P, Gomez, K, Balema, W, Stecklein, S., R, Santiago-Sanchez, G, Krishnamurthy, S, Song, J, Su, X, Ueno, N., T, Tripathy, D, Van Laere, S, Bertucci, F, Vivas-Mejía, P, Woodward, W., A, Debeb, B., G. 2021. Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion.. Molecular oncology, 15 (10), 2752-2765
  • Sharma, P, Abramson, V., G, O'Dea, A, Nye, L, Mayer, I, Pathak, H., B, Hoffmann, M, Stecklein, S., R, Elia, M, Lewis, S, Scott, J, De Jong, J., A, Wang, Y., Y, Yoder, R, Schwensen, K, Finke, K, Heldstab, J, LaFaver, S, Williamson, S., K, Phadnis, M., A, Reed, G., A, Kimler, B., F, Khan, Q., J, Godwin, A., K. 2021. Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 27 (14), 3896-3904
  • Chapman, B., V, Liu, D, Shen, Y, Olamigoke, O., O, Lakomy, D., S, Barrera AMG, Stecklein, S., R, Sawakuchi, G., O, Bright, S., J, Bedrosian, I, Litton, J., K, Smith, B., D, Woodward, W., A, Perkins, G., H, Hoffman, K., E, Stauder, M., C, Strom, E., A, Arun, B., K, Shaitelman, S., F. 2021. Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation.. International journal of radiation oncology, biology, physics
  • Stecklein, S., R, Taniguchi, C., M, Melancon, A., D, Lombe, D, Lishimpi, K, Banda, L, Mwaba, C, Pupwe, G, Mwale, M, Munkupa, H, Kanduza, M, Mule, B, Mwale, A, Court, L, Ohrt, J., D, Kupferman, M., E, Jhingran, A, Msadabwe-Chikuni, S., C. 2020. Radiation Sciences Education in Africa: An Assessment of Current Training Practices and Evaluation of a High-Yield Course in Radiation Biology and Radiation Physics.. JCO global oncology, 6, 1631-1638
  • Stecklein, S., R, Taniguchi, C., M, Melancon, A., D, Lombe, D, Lishimpi, K, Banda, L, Mwaba, C, Pupwe, G, Mwale, M, Munkupa, H, Kanduza, M, Mule, B, Mwale, A, Court, L, Ohrt, J., D, Kupferman, M., E, Jhingran, A, Msadabwe-Chikuni, S., C. 2020. Radiation Sciences Education in Africa: An Assessment of Current Training Practices and Evaluation of a High-Yield Course in Radiation Biology and Radiation Physics.. JCO global oncology, 6, 1631-1638
  • Stecklein, S., R, Sharma, P. 2020. Last but not least: antibody-drug conjugates in hormone receptor-positive metastatic breast cancer.. Annals of oncology : official journal of the European Society for Medical Oncology, 31 (12), 1594-1596
  • Stecklein, S., R, Shaitelman, S., F, Babiera, G., V, Bedrosian, I, Black, D., M, Ballo, M., T, Arzu, I, Strom, E., A, Reed, V., K, Dvorak, T, Smith, B., D, Woodward, W., A, Hoffman, K., E, Schlembach, P., J, Kirsner, S., M, Nelson, C., L, Yang, J, Guerra, W, Dibaj, S, Bloom, E., S. 2019. Prospective Comparison of Toxicity and Cosmetic Outcome After Accelerated Partial Breast Irradiation With Conformal External Beam Radiotherapy or Single-Entry Multilumen Intracavitary Brachytherapy.. Practical radiation oncology, 9 (1), e4-e13